Psychedelic Stocks Hit With Bad Trip After FDA Advisers Reject MDMA Treatment For PTSD
Psychedelic stocks were battered in premarket trading after a panel of experts advising the Food and Drug Administration rejected the approval of MDMA for post-traumatic (PTSD) stress disorder.